Ramachandra Sumant

USNatural personDirector

Insider

Ramachandra Sumant

USNatural personDirector

Transactions

Issuers

Buys / Sells

1/3

Last tx

15 May 2025

Current positions

Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.

Issuer	Shares	Source	Last tx	Detail
MADRIGAL PHARMACEUTICALS, INC.	225,000	reported	11 Mar 2013	tx 2+300,000
Lyell Immunopharma, Inc.	130,000	reported	15 May 2025	tx 3+590,000
HOSPIRA INC	103,603	reported	03 Sept 2015	tx 83+955,746.34−642,415.32

Recent transactions

Date	Type	Issuer	Qty	Price	Signals
15 May 2025	GRANT_AWARD	Lyell Immunopharma, Inc.	130,000	0.00 USD	deriv
21 Mar 2025	PURCHASE	Lyell Immunopharma, Inc.	200,000	0.58 USD
31 Oct 2024	GRANT_AWARD	Lyell Immunopharma, Inc.	260,000	0.00 USD	deriv
03 Sept 2015	EXERCISE	HOSPIRA INC	58,531	37.36 USD

InsiderLens aggregates public information issued by financial regulators (SEC, AMF, FCA, BaFin, AFM, FI, HKEX, ASX). The service constitutes neither investment advice nor a recommendation to buy or sell. Past performance is no guarantee of future results. Investing in financial instruments carries the risk of capital loss.

Current positions

Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.

Issuer	Shares	Source	Last tx	Detail
MADRIGAL PHARMACEUTICALS, INC.	225,000	reported	11 Mar 2013	tx 2+300,000
Lyell Immunopharma, Inc.	130,000	reported	15 May 2025	tx 3+590,000
HOSPIRA INC	103,603	reported	03 Sept 2015	tx 83+955,746.34−642,415.32

Recent transactions

Date	Type	Issuer	Qty	Price	Signals
15 May 2025	GRANT_AWARD	Lyell Immunopharma, Inc.	130,000	0.00 USD	deriv
21 Mar 2025	PURCHASE	Lyell Immunopharma, Inc.	200,000	0.58 USD
31 Oct 2024	GRANT_AWARD	Lyell Immunopharma, Inc.	260,000	0.00 USD	deriv
03 Sept 2015	EXERCISE	HOSPIRA INC	58,531	37.36 USD